NEW YORK, NY / ACCESSWIRE / April 4, 2024 /Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Landos Biopharma, Inc. ("Landos" or the "Company") (NASDAQ:LABP), in connection with its acquisition by AbbVie Inc. (NYSE: ABBV). Under the merger agreement, the Company's shareholders will receive $20.42 per share plus one non-tradable contingent value right ("CVR") per share with a value of up to $11.14 per share, subject to the achievement of a clinical development milestone.
If you own Landos shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:
https://www.weisslaw.co/news-and-cases/labp
Or please contact:
Joshua Rubin, Esq.
Weiss Law
305 Broadway, 7th Floor
New York, NY 10007
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com
Weiss Law is investigating whether (i) the Landos board acted in the best interests of Company shareholders in agreeing to the merger, (ii) the merger consideration adequately compensates Landos' shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.
Weiss Law has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com
SOURCE: Weiss Law
View the original
press release on accesswire.com
